Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

RETA

Reata Pharmaceuticals (RETA)

Reata Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RETA
FechaHoraFuenteTítuloSímboloCompañía
06/10/202315:07Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:RETAReata Pharmaceuticals Inc
28/09/202315:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RETAReata Pharmaceuticals Inc
26/09/202318:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202316:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202315:25Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202315:23Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:RETAReata Pharmaceuticals Inc
26/09/202307:59GlobeNewswire Inc.Biogen Completes Acquisition of Reata PharmaceuticalsNASDAQ:RETAReata Pharmaceuticals Inc
21/09/202309:08Business WireReata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.NASDAQ:RETAReata Pharmaceuticals Inc
14/09/202315:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RETAReata Pharmaceuticals Inc
12/09/202312:20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RETAReata Pharmaceuticals Inc
22/08/202307:00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:RETAReata Pharmaceuticals Inc
11/08/202315:38Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:RETAReata Pharmaceuticals Inc
31/07/202306:20IH Market NewsMonday’s Wall Street Highlights: Palantir Technologies, Walmart, Yellow Corp, J&J, and moreNASDAQ:RETAReata Pharmaceuticals Inc
28/07/202306:05GlobeNewswire Inc.Biogen to Acquire Reata PharmaceuticalsNASDAQ:RETAReata Pharmaceuticals Inc
28/06/202306:20Dow Jones NewsReata Pharma Shares Climb Premarket After FDA OKs Prior-Approval Supplement for SkyclarysNASDAQ:RETAReata Pharmaceuticals Inc
27/06/202318:29Business WireReata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s AtaxiaNASDAQ:RETAReata Pharmaceuticals Inc
26/06/202315:47Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RETAReata Pharmaceuticals Inc
16/06/202315:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RETAReata Pharmaceuticals Inc
15/06/202318:15Business WireReata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval SupplementNASDAQ:RETAReata Pharmaceuticals Inc
13/06/202317:27Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:RETAReata Pharmaceuticals Inc
13/06/202305:45Business WireReata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development OfficerNASDAQ:RETAReata Pharmaceuticals Inc
09/06/202304:45PR Newswire (US)RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsNASDAQ:RETAReata Pharmaceuticals Inc
07/06/202315:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RETAReata Pharmaceuticals Inc
07/06/202304:45PR Newswire (US)INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Reata Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: RETA)NASDAQ:RETAReata Pharmaceuticals Inc
06/06/202315:31Business WireReata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:RETAReata Pharmaceuticals Inc
15/05/202315:36Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:RETAReata Pharmaceuticals Inc
10/05/202305:40Business WireReata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development ProgramsNASDAQ:RETAReata Pharmaceuticals Inc
02/05/202316:45Business WireReata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023NASDAQ:RETAReata Pharmaceuticals Inc
28/04/202305:23Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RETAReata Pharmaceuticals Inc
28/04/202305:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RETAReata Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RETA

Su Consulta Reciente

Delayed Upgrade Clock